Editorial: Optimizing the outcomes of adjuvant radioiodine therapy in differentiated thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 9, 2002, Pages 4059-4062

  Sherman, Steven I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; RADIOACTIVE IODINE; THYROGLOBULIN; THYROID HORMONE; DIAGNOSTIC AGENT; THYROTROPIN;

BASOLATERAL MEMBRANE; CANCER ADJUVANT THERAPY; DOSIMETRY; EDITORIAL; OUTCOMES RESEARCH; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICLE CELL; ADJUVANT THERAPY; HUMAN; NOTE; THYROID TUMOR; TREATMENT OUTCOME;

HUMANS; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME;

EID: 0036736792     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021100     Document Type: Editorial

References (13)

1. Cavalieri RR 1997 Iodine metabolism and thyroid physiology: current concepts. Thyroid 7:177-181
2. Maxon HR, Thomas SR, Samaratunga RC 1997 Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 183-188
3. 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 50:734-739
4. Schlumberger M, Charbord P, Fragu P, Gardet P, Lumbroso J, Parmentier C, Tubiana M 1983 Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. J Clin Endocrinol Metab 57:148-151
5. 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol Metab 53:1199-1206
6. 131I uptake after subtotal thyroidectomy. J Clin Endocrinol Metab 50:502-506
7. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon III HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885
8. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428
9. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. 87:4063-4068
10. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501
11. 131I activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097
12. Samuel AM, Rajashekharrao B 1994 Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 35:1944-1950
13. Schlesinger T, Flower MA, McCready VR 1989 Radiation dose assessments in radioiodine (131) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid. Radiother Oncol 14:35-41